Category - Developments

3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) has successfully completed internal analytical assay validation for its Hodgkin’s lymphoma (HL) test (Telo-HL) according to FDA guidelines. Assay validation of Telo...

Jaguar Animal Health (NASDAQ:JAGX) has entered an exclusive, 60-day evaluation period, beginning April 3, with a leading multinational animal health pharmaceutical firm regarding Equilevia, Jaguar’s drug product...

IntelGenx (OTCQX:IGXT; TSXV:IGX) announced that Eli Lilly granted IntelGenx’s VersaFilm an exclusive license for a tadalafil film product under its 6,943,166 erectile dysfunction (ED) dosing patent. Any exclusivity...

Profound Medical (OTCQX:PRFMF;TSXV:PRN) announced the first TULSA-PRO patient paid procedure has been successfully conducted at the ALTA Klinik in Bielefeld, Germany under the supervision of Dr. Agron Lumiani. TULSA-PRO...

Ortho Regenerative Technologies presented results of four key scientific studies at the 2017 Orthopaedic Research Society annual meeting in San Diego, validating its product’s ability to improve the repair of...

3D Signatures (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) announced that clinical study results confirm that based on a swab from the inside of a patient’s cheek, its TeloView software platform has the ability to identify patients...

Profound Medical (OTCQX:PRFMF; TSXV:PRN) has successfully completed the first sale of a TULSA-PRO system in Finland to the Turku University Hospital, in collaboration with Royal Philips, who is working in partnership...

3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) recently made the final payment to CancerCare Manitoba (CCMB) for the purchase of intellectual property. All patents were assigned from CCMB to 3DS in June 2014. Quarterly...

Jaguar Animal Health (NASDAQ:JAGX) has submitted a formal request to the FDA’s Center for Veterinary Medicine for a determination whether Canalevia qualifies under the requirements of the Minor Use and Minor Species...

RepliCel Life Sciences (OTCQB:REPCF; TSXV:RP; FRA:P6P2) has successfully completed its first-in-human clinical study of the company’s autologous cell therapy for the treatment of androgenetic alopecia (pattern...